This clinical trial is focused on studying a condition called Polycythemia Vera, a rare blood disorder where the body produces too many red blood cells. This can lead to complications such as blood clots. The study is testing a new treatment called Rusfertide, also known by its code name PTG-300. Rusfertide is given as an injection under the skin and is designed to help control the number of red blood cells in the body.

The purpose of the study is to evaluate how safe and effective Rusfertide is in helping patients with Polycythemia Vera maintain control over their hematocrit levels, which is the proportion of red blood cells in the blood. Participants in the study will receive either Rusfertide or a placebo, which looks like the treatment but does not contain the active substance. The study will last for a period of time, during which participants will receive regular injections and have their blood monitored to see how well the treatment is working.

Throughout the study, the main goal is to see if Rusfertide can reduce the need for phlebotomies, which are procedures to remove blood from the body to lower red blood cell levels. The study will also look at other factors, such as changes in fatigue levels and overall well-being. This research aims to provide more information about the potential benefits of Rusfertide for people living with Polycythemia Vera.